Literature DB >> 30686589

Progress in the application of exosomes as therapeutic vectors in tumor-targeted therapy.

Xudong Xie1, Hongpei Wu1, Mei Li2, Xiaojun Chen3, Xiaoyun Xu3, Wenkai Ni1, Cuihua Lu1, Runzhou Ni1, Baijun Bao4, Mingbing Xiao5.   

Abstract

Cancer is the second leading cause of death in the world with a high annual incidence level. Researchers have been working on developing treatments for cancer. Targeted therapy is an emerging treatment modality that is more novel than surgery, radiotherapy and chemotherapy. In targeted therapy, exogenous nanoscale microparticles are applied as carriers for drugs or genes. However, conventional particles have certain limitations attributed to non-specific cytotoxicity, biocompatibility and low delivery efficacy in individual therapeutic vector systems. Exosomes are small vesicles secreted by various cells that consist of lipid bilayer membranes without organelles. Due to their excellent biocompatibility, exosomes have received increased attention in recent years for targeted therapy applications. This review briefly introduces the current status of targeted therapy, and exosomes are introduced by their structural characteristics, physiological effects and separation methods. This review also discusses the applications of engineered exosomes derived from different cells in the field of targeted therapies and compares the two-way regulation of mesenchymal stromal cell-derived exosomes in tumor therapy.
Copyright © 2019 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HEK293 cell; cancer; exosome; mesenchymal stromal cell; targeted therapy; therapeutic cargos; therapeutic vector

Mesh:

Year:  2019        PMID: 30686589     DOI: 10.1016/j.jcyt.2019.01.001

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  4 in total

1.  Extracellular Vesicles as Drug Delivery System for Treatment of Neurodegenerative Disorders: Optimization of the Cell Source.

Authors:  Matthew J Haney; Yuling Zhao; John K Fallon; Wang Yue; Samuel M Li; Emily E Lentz; Dorothy Erie; Philip C Smith; Elena V Batrakova
Journal:  Adv Nanobiomed Res       Date:  2021-06-29

2.  Human umbilical cord mesenchymal stem cell-derived exosomes carrying hsa-miRNA-128-3p suppress pancreatic ductal cell carcinoma by inhibiting Galectin-3.

Authors:  X Xie; J Ji; X Chen; W Xu; H Chen; S Zhu; J Wu; Y Wu; Y Sun; W Sai; Z Liu; M Xiao; B Bao
Journal:  Clin Transl Oncol       Date:  2021-11-23       Impact factor: 3.405

Review 3.  Preclinical Experimental Applications of miRNA Loaded BMSC Extracellular Vesicles.

Authors:  Zafer Cetin; Eyup I Saygili; Gokhan Görgisen; Emel Sokullu
Journal:  Stem Cell Rev Rep       Date:  2021-01-04       Impact factor: 5.739

Review 4.  Long Non-coding RNA DANCR as an Emerging Therapeutic Target in Human Cancers.

Authors:  Shi-Jia Jin; Ming-Zhu Jin; Bai-Rong Xia; Wei-Lin Jin
Journal:  Front Oncol       Date:  2019-11-15       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.